CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.8, 2021 (SCI-Expanded)
Article / Article
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Bcl2, Inhibitor, Venetoclax, Acute myeloid leukemia, Real life, LOW-DOSE CYTARABINE, OLDER PATIENTS, BCL-2 INHIBITION, AZACITIDINE, SURVIVAL, CARE, AML
Bursa Uludag University Affiliated:
Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.